The U.S. Food and Drug Administration approved Pfizer’s Xalkori (crizotinib) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase-positive.
The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
Verastem signed a definitive deal to sell the company’s global commercial and development rights for Copiktra (duvelisib) to Secura Bio.
The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
The U.S. Food and Drug Administration granted orphan drug designation to AFM13, Affimed N.V.’s lead CD30- and CD16A-binding innate cell engager, for the treatment of patients with T-cell lymphoma.
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
AstraZeneca shares rose 2.7 percent after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie.